Nicholas Hornstein, Assistant Professor of Medical Oncology at Northwell Health, posted on X:
“New drugs taking the stage!
Albumin-bound docetaxel (HB1801) vs docetaxel for 2/3L gastric/GEJ 50% improvement in ORR!
- ORR 21.5% vs 14.3%
- Minimal increase in mPFS
- mPFS 4mo vs 2.7 mo
OS non-significant between arms. Side effects similar.
More work to be done but some progress along the way.”
